Asunto(s)
Anticuerpos Antibacterianos/inmunología , Formación de Anticuerpos/inmunología , Síndromes de Inmunodeficiencia/inmunología , Polisacáridos Bacterianos/inmunología , Salmonella typhi/inmunología , Vacunas Tifoides-Paratifoides/inmunología , Adulto , Agammaglobulinemia/inmunología , Anciano , Inmunodeficiencia Variable Común/inmunología , Ensayo de Inmunoadsorción Enzimática , Femenino , Interacciones Huésped-Patógeno/efectos de los fármacos , Interacciones Huésped-Patógeno/inmunología , Humanos , Inmunoglobulina G/inmunología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Salmonella typhi/fisiología , Fiebre Tifoidea/inmunología , Fiebre Tifoidea/microbiología , Fiebre Tifoidea/prevención & control , Vacunas Tifoides-Paratifoides/administración & dosificación , Vacunación/métodos , Adulto JovenRESUMEN
BACKGROUND: A hypersensitivity reaction (HSR) is associated with abacavir (ABC), a nucleoside reverse transcriptase inhibitor. Genetic association of ABC HSR with the presence of HLA-B*5701 has been demonstrated in PREDICT-1 study, showing a prevalence of 5.6% in HIV-infected population. However the prevalence of this allele in HIV-infected patients in Spain has not been established yet. METHOD: This is a cross-sectional epidemiological study that included 1,198 patients in 74 centers that serve the HIV-infected population of Spain. HLA-B*5701 was checked both in the hospital lab and one central lab, showing an overall prevalence of this allele of 6%. RESULTS: HLA-B*5701 was most prevalent in Caucasian population (6.5%). Concordance between the local and central lab was very high for positive and negative results (95.7% and 99.3%, respectively). CONCLUSION: These aspects define this test as a useful tool for the management of HIV-infected patients.
Asunto(s)
Didesoxinucleósidos/efectos adversos , Hipersensibilidad a las Drogas/genética , Infecciones por VIH/tratamiento farmacológico , Antígenos HLA-B/genética , Inhibidores de la Transcriptasa Inversa/efectos adversos , Adulto , Anciano , Estudios Transversales , Didesoxinucleósidos/uso terapéutico , Hipersensibilidad a las Drogas/epidemiología , Femenino , Pruebas Genéticas , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Inhibidores de la Transcriptasa Inversa/uso terapéutico , España/epidemiologíaRESUMEN
OBJECTIVE: To analyze the impact of HLA matching in both patient and graft evolution after LDLT. MATERIAL AND METHODS: Twenty recipients underwent LDLT with follow-up of 3 to 30 months. HLA typing was performed on all donor-recipient pairs; class I antigens were typed using serological methods and class II loci (DRB1 and DQB1) using low-resolution molecular typing. Recipient sera were cross-matched with donor lymphocytes. Antigen mismatches were analyzed for each locus individually, for each class as a whole and for HLA class I immunogenic triplets according to HLA Matchmaker software. RESULTS: Eighteen of 20 donor-recipient pairs were HLA haploidentical. All but one of the recipients had a negative cross-match before transplantation. While there was not a statistically significant correlation between HLA class I mismatches and the incidence of acute rejection episodes, HLA class II matching in DRB1 and DQB1 loci appeared to be associated with a higher incidence of acute rejection episodes after LDLT. Both host-versus-graft (HvG) and graft-versus-host (GvH) HLA class II compatibilities correlated with rejection episodes, especially for the GvH direction. CONCLUSIONS: HLA class II matching for DRB1 and DQB1 loci appears to be associated with a higher incidence of acute rejection episodes after LDLT. In this study, mismatches in class I HLA antigens are not related to an higher incidence of acute rejection episodes nor other complications after LDLT. Further studies are needed to unveil the role of HLA matching in LDLT.
Asunto(s)
Antígenos de Histocompatibilidad Clase II/inmunología , Trasplante de Hígado/inmunología , Donadores Vivos , Adolescente , Adulto , Anciano , Femenino , Antígenos HLA-DQ/análisis , Cadenas beta de HLA-DQ , Prueba de Histocompatibilidad , Humanos , Lactante , Masculino , Núcleo FamiliarRESUMEN
BACKGROUND/AIMS: Markers for hepatitis C virus are often detectable in patients suffering chronic hepatitis with liver-kidney microsomal type 1 antibodies. Several authors have suggested that two subsets of those patients can be defined: a) hepatitis C virus negative and b) hepatitis C virus positive. The aim of this work was to further analyze the possible genetic association, HLA class I and II, in these two groups of patients. METHODS: HLA was analyzed in 49 patients. Class I was studied using a standard lymphocytotoxicity test and in class II a reverse hybridization-based test for DRB1 typing and PCR-SSO for DQB1 typing were used. Sixty healthy Spanish subjects and 39 chronic hepatitis C subjects without anti-LKM1 antibodies were used as control groups for the "a" and "b" subsets, respectively. RESULTS: No significant association was found with class I specificities in either group. DQB1 typing showed a very significant increase of DQ2 in the "a" group (93.3% vs. 48%; RR = 15; Pc = 0.0025), and DRB1 typing from the "b" group revealed a high association with DR7 (82.3% vs. 43.6%; RR = 6; Pc = 0.0086). CONCLUSIONS: Our studies revealed a strong association with DQ2 for the "a" group and for the first time an extremely high association with DR7 antigen for the "b" subset. Hence it is possible to establish a different genetic profile in these two patient groups.